News >

Older Patients With Gastric Cancer May Derive Greater Benefit From Andecaliximab

Brandon Scalea
Published: Friday, Feb 08, 2019

Manish A. Shah, MD

Manish A. Shah, MD
Although the results of a phase III trial evaluating the use of andecaliximab (GS-5745) in patients with gastric cancer were negative overall, a sensitivity analysis has revealed that the agent may be beneficial in older patients, said Manish A. Shah, MD.

In the GAMMA-1 study, results of which were presented at the 2019 Gastrointestinal Cancers Symposium, the addition of the MMP9 inhibitor andecaliximab to FOLFOX6 was not found to improve overall survival (OS) and progression-free survival (PFS) compared with chemotherapy alone in the frontline treatment of patients with HER2-negative gastric cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication